Clinical Trial Update: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C [Phase 3]

View source ↗

Summary

This Clinical Trial Update describes a Phase 3 open-label study of Algeron (cepeginterferon alfa-2b) for treatment-naive chronic hepatitis C patients and indica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Algeron (cepeginterferon alfa-2b)

Snippet

Sponsor: Biocad | Conditions: Hepatitis, Hepatitis C | Phase 3 | Status: COMPLETED